Perspective Therapeutics (CATX) Common Equity (2011 - 2026)

Perspective Therapeutics has disclosed Common Equity across 16 years of filings, most recently posting $323.9 million for Q2 2026.

• In Q2 2026, Common Equity rose 21.89% year-over-year to $323.9 million; the TTM figure through Jun 2026 stood at $323.9 million (up 21.89% YoY), while the FY2025 annual figure was $207.0 million, down 28.77% from the prior year.
• Common Equity came in at $323.9 million for Q2 2026 at Perspective Therapeutics, down from $347.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $347.4 million in Q1 2026 to a low of $54.6 million in Q4 2022.
• Average Common Equity over 5 years is $194.4 million, with a median of $218.5 million recorded in 2024.
• Year-over-year, Common Equity soared 286.63% in 2024 and retreated 28.77% in 2025.
• Over 5 years, Common Equity stood at $54.6 million in 2022, then surged by 37.58% to $75.2 million in 2023, then soared by 286.63% to $290.7 million in 2024, then dropped by 28.77% to $207.0 million in 2025, then jumped by 56.43% to $323.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $323.9 million in Q2 2026, $347.4 million in Q1 2026, and $207.0 million in Q4 2025.